|Day Low/High||42.34 / 43.38|
|52 Wk Low/High||33.20 / 45.81|
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Some groups that have been in horrendous bear market mode finally caught a bid.
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
It becomes difficult for me to tell you where to run in these markets...
Tesla produced 80,000 vehicles in the quarter, according to electrek.
We are about a 20 minutes from the open of a new trading week. Futures are up on news of a trade agreement between Canada and the United States that will lessen overall trade tensions and allow the country to focus on China. Tesla up strongly in pre...
Straying from these names could land you in quicksand as the 4th quarter begins.
Markets were higher Tuesday after starting Tuesday's session off in the green.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
Traders should raise sell stops to just above $40 from below $35.50
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.
Tech is still the equity market's leading sector over three months -- and over most timeframes going back years.
This market clearly has no clue what to buy, with strong GDP growth but challenging trade dynamics and the Facebook and Twitter bombs last week.
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
These blue chips pay shareholders handsomely in the form of dividends and share buybacks.
This market is all about being opportunistic.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.
For Pfizer, China is third largest market and a growing area of concern.
We believe the company has double-digit total return potential at its current price.
Pfizer reorganization could pave way for the company to spin off businesses.
Pfizer announced plans Wednesday to reorganize into three units.
The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.
The bets are coming off one table and going to another amid the tariff news, much to the consternation of the sideliners.
Here are the business stories you must know as U.S. stock futures fall sharply.